RadioNano Therapeutics develops boron-containing inorganic nanoparticles for neutron capture therapy (BNCT), a targeted radiation treatment that selectively destroys cancer cells while minimizing damage to healthy tissue. This approach enables effective treatment of various solid tumors with a single dose, addressing the limitations of traditional radiation therapies that require multiple sessions.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional radiation therapies for cancer often require multiple sessions and can damage healthy tissue surrounding the tumor. This can lead to significant side effects and limit the effectiveness of treatment, especially for solid tumors.
Solution
RadioNano Therapeutics is developing boron-containing inorganic nanoparticles for Boron Neutron Capture Therapy (BNCT), a targeted radiation treatment designed to selectively destroy cancer cells while minimizing damage to healthy tissue. BNCT utilizes the nuclear reaction between non-toxic thermal neutrons and Boron-10 to produce alpha particles and lithium nuclei, which kill cancer cells. The company's novel agent, RN-501, is designed to deliver boron to cancer cells more effectively, potentially reducing side effects and enabling treatment of previously difficult-to-treat cancers. This approach aims to provide a more effective treatment with potentially a single dose, overcoming the limitations of conventional radiation therapy.
Target Audience
The primary target audience includes cancer patients with solid tumors, as well as oncologists and medical centers specializing in advanced radiation therapies.
Features
- Boron-containing inorganic nanoparticles designed for targeted delivery to cancer cells.
- Utilizes Boron Neutron Capture Therapy (BNCT) to selectively destroy cancer cells.
- Aims to minimize damage to surrounding healthy tissue.
- Designed for enhanced accumulation and retention in tumor cells.
- Potentially enables lower doses and shorter treatment times compared to traditional methods.
- Applicable to a range of solid tumors.